Summary & Overview
HCPCS G8969: Documentation of Declined Oral Anticoagulant Therapy
HCPCS Level II code G8969 captures clinician documentation of the patient’s reason(s) for not prescribing an FDA‑approved oral anticoagulant for prevention of thromboembolism. This code is designed to record cases where anticoagulation was considered but not initiated due to factors such as patient preference, informed refusal, or other documented reasons. Nationwide, accurate use of this code supports clinical documentation, quality measurement, and administrative clarity around anticoagulation decisions that deviate from guideline-recommended therapy.
Key payers included in coverage discussions are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical settings where it applies, and which payers are commonly referenced for coverage guidance. The publication outlines benchmarks and policy-relevant considerations for documenting reasons not to prescribe an oral anticoagulant, highlights implications for quality reporting, and summarizes common operational practices related to coding and billing for documented anticoagulation refusal or declination. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G8969 documents the patient reason(s) for not prescribing an oral anticoagulant that is FDA approved for the prevention of thromboembolism (for example, patient preference for not receiving anticoagulation).
-
Service Type: Clinical documentation of anticoagulation decision-making and counseling regarding anticoagulant therapy.
-
Typical Site of Service: Outpatient clinic, physician office, or other ambulatory care settings where medication decisions and shared decision-making occur.
Clinical & Coding Specifications
Clinical Context
A typical patient is an elderly adult with nonvalvular atrial fibrillation who is clinically eligible for an FDA‑approved oral anticoagulant to prevent thromboembolism but declines therapy. The patient presents to a cardiology or primary care clinic for routine follow-up. The clinician documents stroke and bleeding risk assessment (for example, CHA2DS2‑VASc and HAS‑BLED), discusses the benefits and risks of direct oral anticoagulants (DOACs) and warfarin, and records the patient’s stated reason for refusing anticoagulation (such as personal preference, concern about bleeding, difficulty with medication adherence, recent falls, or cost). The clinician documents counseling, alternatives discussed (including antiplatelet therapy if applicable), shared decision‑making, and a plan for follow‑up monitoring and reassessment.
Typical workflow:
-
Patient arrives for follow-up visit and medication review.
-
Clinician reviews indications for anticoagulation and performs risk scoring.
-
Clinician engages in shared decision‑making and documents the patient’s refusal or other reason for not prescribing an FDA‑approved oral anticoagulant.
-
Documentation includes the specific patient reason, counseling provided, any contraindications assessed, and a plan for ongoing monitoring or reconsideration.
-
Code
G8969is appended to the visit billing to indicate documentation of reason(s) for not prescribing an FDA‑approved oral anticoagulant for thromboembolism prevention.